RXi Pharmaceuticals Strengthens NeuVax Patent Portfolio

RXi Pharmaceuticals Corporation RXII announced today that it expanded its patent portfolio with additional patents covering worldwide rights to develop and commercialize NeuVax™ (E75). The patents licensed from The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. cover the use of NeuVax in combination with trastuzumab, and use in low-to-intermediate HER2+ breast cancer patients not eligible for Herceptin therapy. These patents are added to the growing family of patents for RXi to support the development of NeuVax in a variety of indications and countries. NeuVax was discovered at The M. D. Anderson Cancer Center and licensed from MDACC and HJF.